Titan Pharma News (AMEX:TTP)
| Latest Titan Pharma News Headlines | | Date | Time | Source | | | 03/16/2006 | 7:30AM | PRNUS | Titan Pharmaceuticals to Raise $10 Million in Registered Direct Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 16 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that it has obtained commitments to purchase shares of its common stock in a registered direct offering for gross proceeds of approximately $10 million. Under the terms of the transaction, Titan will... More...>> |
| 03/14/2006 | 8:00AM | PRNUS | Titan Reports Fourth Quarter and Year End 2005 Results
SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the fourth quarter and fiscal year ended December 31, 2005.
Net loss for fourth quarter 2005 was approximately $4.0 million, or $0.12 per share, compared to $7.8 million, or $0.24... More...>> |
| 03/07/2006 | 7:30AM | PRNUS | Titan Initiates Controlled Phase II Clinical Study of DITPA in the Treatment of Elevated Cholesterol Levels
SAN FRANCISCO, March 7 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals Inc., announced today the initiation of a Phase II study of DITPA (3,5-diiodothyropropionic acid) in the treatment of elevated cholesterol levels. This study will evaluate the cholesterol-lowering properties of DITPA administered in combination... More...>> |
| 12/15/2005 | 7:30AM | PRNUS | Titan Announces Favorable Results of Pilot Clinical Study of Spheramine(R) Reported in Archives of Neurology
Data Demonstrate Improvement in Motor Function, Activities of Daily Living and Quality of Life
SOUTH SAN FRANCISCO, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that the Archives of Neurology, a publication of the American Medical Association, this week published results... More...>> |
| 12/12/2005 | 7:30AM | PRNUS | Titan Announces that Vanda Pharmaceuticals Initiates Phase III Clinical Trial of Iloperidone
SOUTH SAN FRANCISCO, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Vanda Pharmaceuticals Inc. has initiated a Phase III clinical study of iloperidone, Titan's proprietary antipsychotic agent licensed to Vanda and in development for the treatment of schizophrenia... More...>> |
| 11/09/2005 | 7:00AM | PRNUS | Titan Reports Third Quarter 2005 Results
SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the third quarter ended September 30, 2005.
Net loss for the third quarter of 2005 was approximately $6.4 million, or $0.20 per share, compared to a net loss of approximately $6.3... More...>> |
| 09/29/2005 | 7:00AM | PRNUS | Titan Announces $35 Million Equity Agreement
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) announced today that it has entered into an equity line of credit agreement with Cornell Capital Partners, LP. Under the agreement, Cornell has agreed to provide up to $35 million of funding that can be accessed at... More...>> |
| 09/01/2005 | 7:00AM | PRNUS | Titan Pharmaceuticals Appoints Dr. Joachim-Friedrich Kapp to Its Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Dr. Joachim-Friedrich Kapp has been appointed to the Company's Board of Directors. Dr. Kapp is currently President, Global Business Unit Specialized Therapeutics, at Schering AG, Germany. Schering... More...>> |
| 08/09/2005 | 8:34AM | PRNUS | Titan Reports Second Quarter 2005 Results
SOUTH SAN FRANCISCO, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the second quarter ended June 30, 2005.
Net loss for the second quarter of 2005 was approximately $5.7 million, or $0.18 per share, compared to a net loss of approximately $5.6... More...>> |
| 05/10/2005 | 7:00AM | PRNUS | Titan Reports First Quarter 2005 Results
Titan Reports First Quarter 2005 Results
SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the
first quarter ended March 31, 2005.
Net loss for the first quarter of 2005 was approximately $6.3 million, or $0.19
per share, compared... More...>> |
| 03/14/2005 | 7:00AM | PRNUS | Titan Reports Fourth Quarter and Year End 2004 Results
Titan Reports Fourth Quarter and Year End 2004 Results
SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the
fourth quarter and fiscal year ended December 31, 2004.
Net loss for fourth quarter 2004 was approximately $7.8 million... More...>> |
| 12/14/2004 | 7:00AM | PRNUS | Titan Initiates Randomized, Double Blind, Placebo Controlled Phase II Clinical Study of DITPA In Congestive Heart Failure
Titan Initiates Randomized, Double Blind, Placebo Controlled
Phase II Clinical Study of DITPA In Congestive Heart Failure
SOUTH SAN FRANCISCO, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals Inc., announced today that the company has initiated a
randomized, double blind, Phase IIb study of DITPA, its... More...>> |
| 11/09/2004 | 7:00AM | PRNUS | Titan Reports Third Quarter 2004 Results
Titan Reports Third Quarter 2004 Results
SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the
third quarter ended September 30, 2004.
Net loss for the third quarter of 2004 was approximately $6.3 million, or $0.20
per share, compared... More...>> |
| 08/09/2004 | 6:30AM | PRNUS | Titan Reports Second Quarter 2004 Results
Titan Reports Second Quarter 2004 Results
SOUTH SAN FRANCISCO, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced financial results for the
second quarter ended June 30, 2004.
Net loss for the second quarter of 2004 was approximately $5.6 million, or
$0.17 per share, compared... More...>> |
| 07/26/2004 | 6:30AM | PRNUS | Titan Announces That VA Cooperative Studies Program Initiates Clinical Study of DITPA In Congestive Heart Failure
Titan Announces That VA Cooperative Studies Program Initiates
Clinical Study of DITPA In Congestive Heart Failure
SOUTH SAN FRANCISCO, Calif., July 26 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced that the U.S. Department of
Veterans Affairs (VA) has initiated a 150 patient, randomized... More...>> |
| 07/12/2004 | 10:54AM | PRNUS | Titan Announces FDA Grants Fast Track Designation for Spheramine(R) for Parkinson's Disease
Titan Announces FDA Grants Fast Track Designation for
Spheramine(R) for Parkinson's Disease
SOUTH SAN FRANCISCO, Calif., July 12 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced that the U.S. Food and Drug
Administration (FDA) has granted Fast Track designation for Spheramine for the
treatment... More...>> |
| 06/21/2004 | 8:01AM | PRNUS | Titan Announces Change in Pivanex(R) Phase IIb Study Following Interim Safety Analysis
Titan Announces Change in Pivanex(R) Phase IIb Study Following
Interim Safety Analysis
SOUTH SAN FRANCISCO, Calif., June 21 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) announced today that an interim safety
analysis by an independent data monitoring committee (IDMC) for its Phase IIb
study of Pivanex... More...>> |
| 06/03/2004 | 8:00AM | PRNUS | Titan Announces Positive Results from First Clinical Study of Probuphine(R) in the Treatment of Opiate Addiction
Titan Announces Positive Results from First Clinical Study of
Probuphine(R) in the Treatment of Opiate Addiction
SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced positive results in a recently
completed pilot clinical study evaluating the preliminary... More...>> |
| 05/06/2004 | 9:31AM | PRNUS | Titan Reports First Quarter 2004 Results
Titan Reports First Quarter 2004 Results
SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. today announced financial results for the first quarter
ended March 31, 2004.
Net loss for the first quarter of 2004 was approximately $6.4 million, or $0.22
per share, compared to a net... More...>> |
| 03/26/2004 | 9:52AM | PRNUS | Titan Pharmaceuticals Announces Sale of Common Stock
Titan Pharmaceuticals Announces Sale of Common Stock
SOUTH SAN FRANCISCO, Calif., March 26 /PRNewswire-FirstCall/ -- Titan
Pharmaceuticals, Inc. announced today that it has obtained binding commitments
from a number of select institutional investors and an individual investor to
purchase approximately three million... More...>> |
|
|
|